Enanta Pharmaceuticals Inc
ENTA
Market Cap$354.36M
Close$
$-8.98
164.2% downside
Current Fair Value
164.2% downsideOvervalued by 164.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $354.36 Million |
|---|---|
| Enterprise Value | $17.21 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-6.57 |
| Beta | 1.15 |
| Outstanding Shares | 21,155,983 |
| Avg 30 Day Volume | 257,490 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.56 |
|---|---|
| PEG | -16.81 |
| Price to Sales | 4.67 |
| Price to Book Ratio | 1.56 |
| Enterprise Value to Revenue | 0.23 |
| Enterprise Value to EBIT | -0.12 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly